- Home
- NEN vs CLLS Comparison
NEN vs CLLS Comparison
Compare NEN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
Company Overview
Basic Information| Metric | NEN | CLLS |
|---|---|---|
| Founded | 1977 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 476.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NEN | CLLS |
|---|---|---|
| Price | $64.50 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 2.1K | ★ 115.4K |
| Earning Date | 03-12-2026 | 11-07-2025 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $87,362,592.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | $19.39 | ★ N/A |
| Revenue Growth | 7.63 | ★ 129.04 |
| 52 Week Low | $63.00 | $1.10 |
| 52 Week High | $84.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | NEN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 55.28 |
| Support Level | $63.00 | $4.62 |
| Resistance Level | $64.50 | $5.10 |
| Average True Range (ATR) | 0.87 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.35 | 78.57 |
Price Performance
Historical ComparisonAbout NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.